No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

No­vo Nordisk’s semaglu­tide sig­nif­i­cant­ly re­duced the risk of car­dio­vas­cu­lar events and death in pa­tients with type 2 di­a­betes and chron­ic kid­ney dis­ease in a late …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER